<DOC>
	<DOC>NCT01357252</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy and safety of vildagliptin 50mg qd as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with prior sulfonylurea monotherapy as compared to placebo. This study is aimed at supporting the regulatory approval in China of vildagliptin as combination therapy with sulfonylureas in the treatment of type 2 diabetes.</brief_summary>
	<brief_title>Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1. Confirmed diagnosis of T2DM by standard criteria 2. Patients who have received a stable dose of SU for at least 12 weeks prior to Visit 1 3. HbA1c ≥7.5% to ≤ 11.0% at Visit 1 and Visit 3 (Week 1) 4. Age: ≥18 to ≤ 80 years at Visit 1. 5. BMI ≥ 20 and ≤ 40 kg/m^2 at visit 1. 1. FPG ≥ 270mg/dl (15.0 mmol/L) at Visit 1 or Visit 3 (Week 1) 2. Severe or repetitive hypoglycemia, as defined in section 3.1, during the runin period (between Visit 2 and Visit 4) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>vildagliptin</keyword>
</DOC>